Creating exemption to prescription limitations for mid-level providers
Summary
SB 743 amends West Virginia’s Opioid Reduction Act prescription-limit section to create a narrow exemption for certain hospice-related prescribers. Under the bill, mid-level licensed providers who are employed exclusively by a licensed hospice provider and supervised by a physician medical director would be allowed to prescribe comfort medications, including Schedule II through V controlled substances, without being bound by the bill’s opioid prescription limits when treating hospice patients for end-of-life comfort care.
The bill also requires the physician medical director to oversee and audit the prescribing practices of those mid-level providers and to ensure compliance with controlled substances monitoring database reporting. The measure leaves the broader opioid prescribing restrictions in place for emergency rooms, urgent care, minors, dentists, optometrists, veterinarians, and general practitioners, while preserving existing exceptions for cancer patients, hospice patients, palliative care, long-term care residents, and patients treated for substance use disorder or opioid dependence.
Impact
SB 743 would amend §16-54-4 of the West Virginia Code, the state’s opioid prescription-limitation statute, by adding a hospice-specific exemption for mid-level providers. It would not repeal the general limits on Schedule II opioid prescriptions, but it would carve out a new category of exempt prescribers and settings, affecting hospice providers, physician medical directors, and licensed mid-level practitioners. The bill also reinforces compliance duties tied to the Controlled Substances Monitoring Program Database and places audit responsibility on the supervising physician medical director.
Sentiment
The available record shows no committee debate, votes, or recorded opposition, so the overall sentiment cannot be measured from discussion history. Based on the bill text and stated purpose, the measure appears to be framed as a targeted hospice-care accommodation rather than a broad rollback of opioid restrictions, suggesting a generally practical and limited policy approach.
Contention
The main policy tension is between maintaining strict opioid-prescribing controls and allowing flexibility for end-of-life hospice care. Supporters would likely emphasize patient comfort, continuity of hospice services, and the need for mid-level providers to prescribe necessary medications without being constrained by standard limits. Potential concerns would center on diversion risk, oversight of controlled substances, and whether the exemption could weaken opioid safeguards, which is why the bill requires physician medical director supervision and auditing. No specific stakeholder objections are recorded in the provided materials.
Prohibits pre-approval or precertification of cancer treatments, tests, procedures and prescription drugs covered under health benefits or prescription drug benefits plans.
Requires health care practitioners prescribing opioid medications to limit amount of prescribed medication to seven-day supply, except in certain circumstances.